Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Our team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. We believe that our approach – which targets the underlying molecular pathogenesis of the disease – enables us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of our product candidates.
With the Biologics License Application (BLA) for our lead asset inebilizumab accepted for review by FDA, we are currently preparing for the drug candidate’s potential commercialization. Inebilizumab was studied as a first-line monotherapy treatment for patients with neuromyelitis optica spectrum disorder (NMOSD), and we are exploring its applicability in other indications sharing the autoantibody pathway. In addition, we are advancing clinical studies in diseases of significant unmet medical need including myasthenia gravis, IgG4-related disease, and Sjögren’s syndrome, as well as other conditions such as kidney transplant rejection.